Advertisement

ADVERTISEMENT

Non–Small-Cell Lung Cancer

News
No Difference in Overall Survival Between Immunotherapy Treatment Lengths Among Patients With Advanced NSCLC
07/10/2023

Amber Denham

Amber Denham
Patients with non–small cell lung cancer who are progression-free on immunotherapy may be able to stop therapy at 2 years with no effect on overall survival.
Patients with non–small cell lung cancer who are progression-free on immunotherapy may be able to stop therapy at 2 years with no effect on overall survival.
Patients with non–small cell...
07/10/2023
Oncology
Researchers Demonstrate Promising Efficacy of Lorlatinib in Patients With ALK+ NSCLC
Videos
Researchers Demonstrate Promising Efficacy of Lorlatinib in Patients With ALK+ NSCLC
06/10/2020
David Carbone, MD, PhD, offers his perspective on 2 clinical trials that evaluated the use of lorlatinib in patients with ALK-positive NSCLC.
David Carbone, MD, PhD, offers his perspective on 2 clinical trials that evaluated the use of lorlatinib in patients with ALK-positive NSCLC.
David Carbone, MD, PhD, offers...
06/10/2020
Oncology
Alectinib Extends Survival in Treatment-Naïve Patients With ALK+ NSCLC
Videos
Alectinib Extends Survival in Treatment-Naïve Patients With ALK+ NSCLC
06/04/2020
Yasir Elamin, MD, discusses the findings of a study comparing alectinib with crizotinib in treatment-naïve patients with ALK-positive NSCLC.
Yasir Elamin, MD, discusses the findings of a study comparing alectinib with crizotinib in treatment-naïve patients with ALK-positive NSCLC.
Yasir Elamin, MD, discusses the...
06/04/2020
Oncology
Combining Immuno-Oncology and Standard Chemo in the Treatment of NSCLC
Videos
Combining Immuno-Oncology and Standard Chemo in the Treatment of NSCLC
06/03/2020
Solange Peters, MD, PhD, provides a summation of the Keynote-189, CheckMate 9LA, and CheckMate 227 clinical trials, and what the findings of these studies mean for the treatment of patients with NSCLC.
Solange Peters, MD, PhD, provides a summation of the Keynote-189, CheckMate 9LA, and CheckMate 227 clinical trials, and what the findings of these studies mean for the treatment of patients with NSCLC.
Solange Peters, MD, PhD,...
06/03/2020
Oncology
NGS of Cell-Free Plasma DNA Shows Value in Management of Patients With ALK+ NSCLC
Videos
NGS of Cell-Free Plasma DNA Shows Value in Management of Patients With ALK+ NSCLC
06/02/2020
David Carbone, MD, PhD, talks about the usefulness of NGS for cell-free plasma DNA in patients with ALK-positive NSCLC.
David Carbone, MD, PhD, talks about the usefulness of NGS for cell-free plasma DNA in patients with ALK-positive NSCLC.
David Carbone, MD, PhD, talks...
06/02/2020
Oncology
Recent Advancements in the Treatment of HER2+ NSCLC
Videos
Recent Advancements in the Treatment of HER2+ NSCLC
06/01/2020
Solange Peters, MD, PhD, discusses the DESTINY trial and recent advancements made in the exploration of treatment options for patients with HER2-positive NSCLC.
Solange Peters, MD, PhD, discusses the DESTINY trial and recent advancements made in the exploration of treatment options for patients with HER2-positive NSCLC.
Solange Peters, MD, PhD,...
06/01/2020
Oncology
Videos
Anti–PD-L1 Therapy Not Recommended for Patients With NSCLC, Active Brain Metastases
06/01/2020
David Carbone, MD, PhD, comments on a study evaluating the efficacy of anti–PD1/PD-L1 monotherapy for patients with NSCLC and active brain metastases.
David Carbone, MD, PhD, comments on a study evaluating the efficacy of anti–PD1/PD-L1 monotherapy for patients with NSCLC and active brain metastases.
David Carbone, MD, PhD, comments...
06/01/2020
Oncology
Lorlatinib Shows Promise in Real-World Study of Patients With ALK+ NSCLC
Videos
Lorlatinib Shows Promise in Real-World Study of Patients With ALK+ NSCLC
06/01/2020
Yasir Elamin, MD, talks about how a study examining the real-world use of lorlatinib for ALK-positive NSCLC supports previously reported phase 2 trial data about this drug.
Yasir Elamin, MD, talks about how a study examining the real-world use of lorlatinib for ALK-positive NSCLC supports previously reported phase 2 trial data about this drug.
Yasir Elamin, MD, talks about...
06/01/2020
Oncology
News
LCT With Brigatinib Shows Efficacy in TKI-Naïve Patients With ALK-Positive NSCLC
05/31/2020
Study findings posit LCT with brigatinib as a safe and effective treatment option for patients with ALK-rearranged advanced NSCLC, regardless of the number of metastatic sites.
Study findings posit LCT with brigatinib as a safe and effective treatment option for patients with ALK-rearranged advanced NSCLC, regardless of the number of metastatic sites.
Study findings posit LCT with...
05/31/2020
Oncology
Brigatinib Plus LCT Safe, Feasible for TKI-Naïve Patients With ALK+ NSCLC
Videos
Brigatinib Plus LCT Safe, Feasible for TKI-Naïve Patients With ALK+ NSCLC
05/31/2020
Yasir Elamin, MD, talks about the findings of a study in which LCT plus brigatinib was shown to be an effective treatment for ALK-rearranged advanced NSCLC.
Yasir Elamin, MD, talks about the findings of a study in which LCT plus brigatinib was shown to be an effective treatment for ALK-rearranged advanced NSCLC.
Yasir Elamin, MD, talks about...
05/31/2020
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

ECS
November 8 ⁠–⁠ November 10
Dermatology Week
November 13 ⁠–⁠ November 16
Psych Congress Primary Care Online Series
November 14 ⁠–⁠ November 15
November 23 ⁠–⁠ November 24
December 4 ⁠–⁠ December 5
Great Debates & Updates in Diabetic Foot
December 6 ⁠–⁠ December 7
December 9 ⁠–⁠ December 11
AIBD
December 9 ⁠–⁠ December 11
Psych Congress Primary Care Online Series
December 12 ⁠–⁠ December 13
December 14 ⁠–⁠ December 15
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use